Chimeric Therapeutics Limited

Equities

CHM

AU0000121576

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:12 2024-05-03 am EDT			5-day change	1st Jan Change
0.029 ^AUD	0.00%		0.00%	-17.14%

May. 02	Chimeric Therapeutics Appoints COO; Shares Rise 4%	MT
May. 01	Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%	MT

Chimeric Therapeutics thrilled with ethics approval for brain cancer study

April 27, 2023 at 11:01 am EDT

(via NewsDirect)

Chimeric Therapeutics Ltd (ASX:CHM) CEO Jennifer Chow tells Proactive the company has the ethics review board’s green light to initiate a multi-site Phase 1B clinical trial of CHM 1101 in patients with recurrent and/or progressive glioblastoma multiforme (GBM). CHM sees this as a new chapter in the development of CHM 1101, which will see the company roll-out the two-part Phase 1B clinical study across multiple trial sites.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Chimeric Therapeutics Limited

Chimeric Therapeutics Appoints COO; Shares Rise 4%	May. 01	MT
Chimeric Therapeutics' CEO/Managing Director Steps Down; Shares Plunge 20%	Apr. 30	MT
Chimeric Therapeutics Obtains Patent Application Covering CORE-NK Technology; Shares Up 3%	Apr. 04	MT
Chimeric Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Chimeric Therapeutics Treats First Patient in Phase 1B Leukemia Trial	Feb. 08	MT
Chimeric Therapeutics to Raise AU$3.2 Milion Via Shortfall Placement	Jan. 18	MT
Chimeric Therapeutics Opens Phase 1B Leukemia Trial	Jan. 14	MT
Chimeric Therapeutics Receives AU$7 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%	Jan. 09	MT
Chimeric Therapeutics Secures AU$1 Million via Share Placement Deal	Jan. 04	MT
Chimeric Therapeutics Extends Closing Date of AU$10 Million Entitlement Offer	Nov. 15	MT
Chimeric Therapeutics Doses First Patient in Phase 1B Clinical Trial for Brain Cancer	Nov. 01	MT
Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101	23-10-31	CI
Australian Shares Rebound Ahead of US Fed Policy Meeting	23-10-31	MT
US FDA Gives Green Signal to Chimeric Therapeutics' IND Application for Gastrointestinal Cancer Drug; Shares Jump 65%	23-10-30	MT
Chimeric Therapeutics to Raise AU$10 Million from Entitlement Offer	23-10-25	MT
Chimeric Therapeutics Signs Deal to Support Leukemia Trial	23-09-13	MT
Chimeric Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Chimeric Therapeutics Limited Announces Board Changes	23-08-30	CI
Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive Director	23-08-02	CI
Chimeric Therapeutics Secures Japanese Patent Allowance for Chlorotoxin	23-07-27	MT
Chimeric Therapeutics Limited Announces Board Changes	23-07-12	CI
Chimeric Therapeutics Secures Up to AU$12.6 Million for Clinical Trial, Therapy	23-06-23	MT
Chimeric Therapeutics Completes Share Purchase Plan; Shares Rise 6%	23-06-22	MT
Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical Trial	23-06-04	CI
Chimeric Therapeutics Launches New Phase 1B Clinical Trial for Glioblastoma Multiforme	23-06-04	MT

Chart Chimeric Therapeutics Limited

Duration

Period

More charts

Company Profile

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase I clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of four NK and CAR NK assets with plans for Phase I clinical trials in solid tumors and blood cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-09-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.029 AUD

Average target price

0.15 AUD

Spread / Average Target

+417.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHIMERIC THERAPEUTICS LIMITED	-17.14%	16.16M
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B

Bio Therapeutic Drugs